Advancing their research and development for medicinal cannabis applications, Little Green Pharma (ASX: LGP) has joined the global movement for use of psychedelics for treatment of mental illness having secured regulatory approval to supply psilocybin. The approvals come in the form of a Schedule 9 licence granted by the WA Department of Health which enables
Read More
Harbouring more MDMA than music festival goers, the University of Western Australia (UWA) is leading the way in research around the use of MDMA as a psychedelic medication. Clinical drug development and care delivery company Emyria (ASX: EMD) has today announced a partnership with UWA, confirming access to their library of MDMA- like compounds developed
Read More
Once upon a time, stress ensured our survival. When faced with a dangerous situation our body responds instantly- heart rate increases, blood pressure climbs and muscles tighten as the body prepares to deal with the bear/ exam you’ve been presented with. In the modern world we are faced with a disproportionately higher amount of exams
Read More
According to the Australian Department of Health, half of us will experience some form of mental illness in our lifetime. Treatment is somewhat limited to prescription medications and psychotherapy. However, the current mental health crisis has seen researchers and practitioners alike wondering- is there a better way to approach these frighteningly common conditions? Enter psychedelics,
Read More